We invite you to participate in a multicenter observational study titled "Efficacy and safety of brigatinib in the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Prospective multicenter observational study."

To start the study, it is necessary to conclude an online agreement, so please register and follow the instructions appearing on the computer screen.

After successful registration and electronic signing of the agreement, please log in using the data obtained during the account setup process.